Scans

Tools

Home

Charts

Watchlist

Products

Fredun Pharmaceuticals Ltd

FREDUN

BSE

₹1,430.05-3.18%19 Oct 2026

Reports

Pharma Formulations

Fredun Pharmaceuticals Ltd

FREDUN

BSE

₹1,430.05

-3.18%

19 Oct 2026

SOICxStockScans Reports

Ask AI

Pharma Formulations

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Guidance Report: Management guidance vs outcomes.Forensic Report: Accounting quality and red flags.Deep Dive Report: In-depth business analysis.

Fredun Pharmaceuticals is a pharmaceutical manufacturer that has spent nearly four decades turning its own factory floor into a diversified healthcare platform - it started manufacturing allopathic formulations in 1994, survived a near-collapse when its partners moved away, and rebuilt itself by owning the brands and product registrations it once only manufactured. Today, the company operates under the tagline “Compassionate Healthcare” and has expanded from generic drugs into pet healthcare, nutrition, skincare, mobility aids, and premium wellness, all anchored by a manufacturing base in Palghar, Maharashtra, that produces close to 2,000 different products in-house. The recurring approach is to take a core manufacturing capability - whether in powders, granules, or creams - and build consumer-facing brands on top of it, so that the company captures the value of both the molecule and the label.

Business segments

Four engines built on a shared manufacturing backbone - a generics export and domestic branded-generics business that pays the bills, a pet-care ecosystem that is the company’s most ambitious growth bet, a suite of consumer-health brands spanning nutrition, skincare and mobility, and an early-stage premium wellness platform targeting longevity and hormone health.

1. Generics and branded generics: the foundation that funds everything else

Fredun makes finished-dose medicines - tablets, capsules, creams, and liquids - and sells them in 52 countries under its own registered brand names, which means its customers are tied to the company for as long as the registration is valid.

Owns the registration, not just the factory - the company holds over 813 product registrations globally, with more than 1,426 additional ones under development, and roughly 65% of export revenue comes from products registered in Fredun’s own name rather than made for a third party; that turns a one-off manufacturing contract into a recurring stream because the overseas distributor cannot easily switch suppliers.
A broad medicine cabinet - the portfolio spans 34 therapeutic areas, from anti-malarials and anti-retrovirals to diabetes and cardiovascular drugs, including advanced molecules like Dolutegravir, Sofosbuvir, and Tenofovir Alafenamide; this breadth means the company is not dependent on any single disease category or patent cycle.
Seven granulation suites and counting - the Palghar plant houses 13 compression machines, 37 packaging lines, and a recently added seventh granulation unit that boosted daily output by two tonnes; a fifth factory, initially 40,000 square feet, is being built for veterinary, nutraceutical, and specialty export production and is expected to start in October 2026.

2. Freossi pet healthcare: the company’s most strategically important growth platform

Fredun has built India’s only integrated pet-care ecosystem - it makes the medicines, the food, the grooming products, and even runs a 24/7 diagnostic centre with a pet ambulance, all under one brand.

Built on a unique raw material - the division’s products are anchored on MCHC (Microcrystalline Hydroxyapatite Complex), a natural calcium-phosphorus compound with over 60 years of clinical evidence, and Fredun is the largest manufacturer of MCHC in India, giving it a cost and supply advantage that no local competitor can easily replicate.
From 4 products to 76-plus in four years - the Freossi range now covers antifungal creams, heart-failure chewables for dogs, liver and urinary health syrups, immunity boosters, and a full grooming line that includes anti-tick spray and plant-based wound cleansers; the brand has also entered the large-animal segment with lactation and joint supplements for cattle and horses.
Bought a route to the consumer’s doorstep - through its subsidiary Fredun Retail, the company acquired One Pet Stop, a tech-enabled at-home grooming service that uses temperature-controlled vans and certified groomers to serve over 4,000 pet owners; this gives Freossi a direct B2C channel and a mobile app for booking and health reminders.

3. Consumer health brands: nutrition, skincare, and mobility aids

Three young divisions - nutraceuticals, cosmeceuticals, and mobility products - share a common playbook: manufacture in-house, sell through doctors and chemists, and use the same distribution network that carries the company’s generic drugs.

Prescription-driven nutrition - the Fredun Nutrition range of 36-plus products, including a lactation booster called Mamalait and a PCOS management formula, is promoted ethically to doctors, which means the purchase decision starts in the clinic rather than on a supermarket shelf; the division has already shipped its first export orders to Nigeria and West Africa under its own brand name.
Emu Oil as a differentiator - the BeautyFred and Bird n Beauty skincare lines use humanely sourced, chemically purified Emu Oil as a signature ingredient, and the company claims to be the first in India to launch Emu Oil-enriched personal care products at scale; the dedicated factory has already produced over one million bottles.
A pain balm for the masses - Chuu Balm, developed over 12 months of clinical trials by 14 scientists, is priced specifically for economically disadvantaged communities and sold through OTC stores; the automatic manufacturing unit was commercialised with orders for nine million units, and the product rides on the same pharma distribution channel that competitors like Visco and Timo lack.
Mobility aids with a logistics edge - the Fredun Mobility division currently has 143 SKUs - knee caps, lumbo-sacral belts, nebulisers, and digital thermometers - and because it uses the Fredun Gx distribution network, it reaches chemist shops that standalone orthopaedic brands cannot access efficiently.

4. Premium wellness and specialty therapeutics: an early bet on longevity

Two brands launched simultaneously in May 2026 - DAULCÉL and a Hormone Range - mark the company’s entry into cellular aging and doctor-led hormone therapy, built on a direct-to-patient digital model.

India’s first NAD+ wellness line - DAULCÉL is positioned around NAD+ science, a molecule linked to cellular repair and healthy aging, and is described by the company as the first such offering in the Indian market.

Group structure and partners

Fredun Pharmaceuticals is a standalone listed entity that has only recently begun building a subsidiary structure, all of it aimed at moving closer to the end consumer.

The company is a wholly owned subsidiary of the Fredun Group and is listed on the BSE, with founder Fredun Medhora as Managing Director and Dr. Daulat Medhora - a Ph.D. chemist - as Chairperson and Joint Managing Director.
The company has a technology-transfer partnership with a UAE firm for manufacturing direct-compressible granules and ready-to-fill pellets, and marketing tie-ups with seven other manufacturers for products it does not make itself.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹2,365Cr

Close Price

₹1,430.05

Industry

Pharma Formulations

Price To Earnings

50.05

Price To Sales

3.16

Revenue

₹748Cr

Rev Gr TTM

Revenue Growth TTM

—

PAT Gr TTM

PAT Growth TTM

—

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	0	167	120	145	161	213	228
Growth YoY Revenue Growth YoY%						27.3	90.5
Expenses ExpensesCr	0	150	103	123	135	184	196
Operating Profit Operating ProfitCr	0	17	17	22	26	29	33
OPM OPM%		10.3	14.2	15.4	16.4	13.6	14.3
Other Income Other IncomeCr	0	0	0	0	0	0	0
Interest Expense Interest ExpenseCr	0	8	7	8	11	14	9
Depreciation DepreciationCr	0	2	1	2	2	3	4
PBT PBTCr	0	7	9	13	14	11	21
Tax TaxCr	0	1	2	3	4	0	7
PAT PATCr	0	6	7	9	10	11	13
Growth YoY PAT Growth YoY%						79.7	93.9
NPM NPM%		3.6	5.7	6.5	6.5	5.1	5.8
EPS EPS₹	0.0	4.2	4.8	6.7	7.4	6.6	7.9

Quarter	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	0	167	120	145	161	213	228
Growth YoY Revenue Growth YoY%						27.3	90.5
Expenses ExpensesCr	0	150	103	123	135	184	196
Operating Profit Operating ProfitCr	0	17	17	22	26	29	33
OPM OPM%		10.3	14.2	15.4	16.4	13.6	14.3
Other Income Other IncomeCr	0	0	0	0	0	0	0
Interest Expense Interest ExpenseCr	0	8	7	8	11	14	9
Depreciation DepreciationCr	0	2	1	2	2	3	4
PBT PBTCr	0	7	9	13	14	11	21
Tax TaxCr	0	1	2	3	4	0	7
PAT PATCr	0	6	7	9	10	11	13
Growth YoY PAT Growth YoY%						79.7	93.9
NPM NPM%		3.6	5.7	6.5	6.5	5.1	5.8
EPS EPS₹	0.0	4.2	4.8	6.7	7.4	6.6	7.9

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	454	635	748
Growth Revenue Growth%		40.0
Expenses ExpensesCr	401	545	637
Operating Profit Operating ProfitCr	52	91	110
OPM OPM%	11.6	14.3	14.8
Other Income Other IncomeCr	2	4	0
Interest Expense Interest ExpenseCr	22	39	41
Depreciation DepreciationCr	5	8	10
PBT PBTCr	27	47	59
Tax TaxCr	8	14	15
PAT PATCr	20	33	44
Growth PAT Growth%		65.3
NPM NPM%	4.3	5.1	5.9
EPS EPS₹	14.9	22.3	28.6

Financial Year	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	454	635	748
Growth Revenue Growth%		40.0
Expenses ExpensesCr	401	545	637
Operating Profit Operating ProfitCr	52	91	110
OPM OPM%	11.6	14.3	14.8
Other Income Other IncomeCr	2	4	0
Interest Expense Interest ExpenseCr	22	39	41
Depreciation DepreciationCr	5	8	10
PBT PBTCr	27	47	59
Tax TaxCr	8	14	15
PAT PATCr	20	33	44
Growth PAT Growth%		65.3
NPM NPM%	4.3	5.1	5.9
EPS EPS₹	14.9	22.3	28.6

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	5	5
Reserves ReservesCr	137	259
Current Liabilities Current LiabilitiesCr	328	297
Non Current Liabilities Non Current LiabilitiesCr	18	67
Total Liabilities Total LiabilitiesCr	487	642
Current Assets Current AssetsCr	427	498
Non Current Assets Non Current AssetsCr	60	144
Total Assets Total AssetsCr	487	642

Financial Year	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	5	5
Reserves ReservesCr	137	259
Current Liabilities Current LiabilitiesCr	328	297
Non Current Liabilities Non Current LiabilitiesCr	18	67
Total Liabilities Total LiabilitiesCr	487	642
Current Assets Current AssetsCr	427	498
Non Current Assets Non Current AssetsCr	60	144
Total Assets Total AssetsCr	487	642

Consolidated

Standalone

Financial Year	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	-17	12
Investing Cash Flow Investing Cash FlowCr	-6	-74
Financing Cash Flow Financing Cash FlowCr	27	121
Net Cash Flow Net Cash FlowCr	4	60
Free Cash Flow Free Cash FlowCr	-23	-62
CFO To PAT CFO To PAT%	-84.1	36.5
CFO To EBITDA CFO To EBITDA%	-31.6	13.1

Financial Year	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	-17	12
Investing Cash Flow Investing Cash FlowCr	-6	-74
Financing Cash Flow Financing Cash FlowCr	27	121
Net Cash Flow Net Cash FlowCr	4	60
Free Cash Flow Free Cash FlowCr	-23	-62
CFO To PAT CFO To PAT%	-84.1	36.5
CFO To EBITDA CFO To EBITDA%	-31.6	13.1

Consolidated

Standalone

Financial Year	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	316	915	2,365
Price To Earnings Price To Earnings	16.0	28.1	50.0
Price To Sales Price To Sales	0.7	1.4	3.2
Price To Book Price To Book	2.2	3.5	8.8
EV To EBITDA EV To EBITDA	9.1	11.8	23.6
Profitability Ratios Profitability Ratios
GPM GPM%	23.4	26.1	26.1
OPM OPM%	11.6	14.3	14.8
NPM NPM%	4.3	5.1	5.9
ROCE ROCE%	16.2	17.7	17.7
ROE ROE%	14.0	12.3	12.3
ROA ROA%	4.0	5.1	5.1
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	316	915	2,365
Price To Earnings Price To Earnings	16.0	28.1	50.0
Price To Sales Price To Sales	0.7	1.4	3.2
Price To Book Price To Book	2.2	3.5	8.8
EV To EBITDA EV To EBITDA	9.1	11.8	23.6
Profitability Ratios Profitability Ratios
GPM GPM%	23.4	26.1	26.1
OPM OPM%	11.6	14.3	14.8
NPM NPM%	4.3	5.1	5.9
ROCE ROCE%	16.2	17.7	17.7
ROE ROE%	14.0	12.3	12.3
ROA ROA%	4.0	5.1	5.1
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	GUFICBIO	KPL	INDSWFTLAB	FREDUN	INDOCO	SAIPARENT	BETA
Market CapitalizationMkt CapCr	4,056	3,493	3,060	2,365	2,183	2,134	1,906
Close PriceClose₹	404.45	3,366.00	351.90	1,430.05	236.50	483.00	1,719.60
IndustryIndustry	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations
Price To EarningsPE	55.25	43.10	51.60	50.05	739.06	102.77	38.90
Price To SalesPS	4.13	6.30	4.60	3.16	1.17	5.60	4.65
RevenueRevenueCr	981	554	665	748	1,873	381	410
Revenue Growth TTMRev Gr TTM%	16.7%	37.9%	54.0%		12.0%
PAT Growth TTMPAT Gr TTM%	18.7%	86.8%	-74.7%		102.7%

	GUFICBIO	KPL	INDSWFTLAB	FREDUN	INDOCO	SAIPARENT	BETA
Market CapitalizationMkt CapCr	4,056	3,493	3,060	2,365	2,183	2,134	1,906
Close PriceClose₹	404.45	3,366.00	351.90	1,430.05	236.50	483.00	1,719.60
IndustryIndustry	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations
Price To EarningsPE	55.25	43.10	51.60	50.05	739.06	102.77	38.90
Price To SalesPS	4.13	6.30	4.60	3.16	1.17	5.60	4.65
RevenueRevenueCr	981	554	665	748	1,873	381	410
Revenue Growth TTMRev Gr TTM%	16.7%	37.9%	54.0%		12.0%
PAT Growth TTMPAT Gr TTM%	18.7%	86.8%	-74.7%		102.7%

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Jun 26